ACE-031 1mg
ActRIIB Inhibitor for Muscle Mass and Bone Research
ACE-031 is a soluble form of ActRIIB that acts as a myostatin and GDF-11 trap, blocking negative regulators of muscle growth. It demonstrated significant muscle and bone mass increases in clinical trials before development was halted for reasons unrelated to efficacy.
ActRIIB Inhibitor for Muscle Mass and Bone Research
ACE-031 (sotatercept analogue) sequesters myostatin, activin A, GDF-8, and GDF-11 — all ligands that inhibit muscle and bone mass. By blocking these negative regulators, it produces marked increases in lean mass and bone mineral density in preclinical and clinical studies.
As one of the most studied compounds in the longevity research space, ACE-031 has attracted sustained scientific interest across Myostatin pathway research, Muscle hypertrophy studies, Bone mass research. Peer-reviewed evidence indicates that phase 2 trial: significant muscle mass increase vs placebo, which has positioned ACE-031 as a reference standard for researchers exploring myostatin pathway research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
ACE-031 Documented Benefits: 3 Documented Mechanisms
Myostatin Inhibition
Sequesters myostatin and related GDFs to remove the primary brake on skeletal muscle hypertrophy.
Lean Mass Increase
Phase 1 trials showed significant muscle mass gains within weeks of administration.
Bone Density
Simultaneously increases bone mineral density by blocking inhibitory signals in osteoblast regulation.
How ACE-031 Works: Molecular Mechanism & Pathway
Soluble ActRIIB decoy receptor sequestering myostatin, activin A, and GDF-8/11, releasing their inhibitory brake on muscle and bone mass.
The 3 primary research pathways identified for ACE-031 — Myostatin Inhibition, Lean Mass Increase, Bone Density — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that simultaneous bone density improvements, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, ACE-031's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
ACE-031 is routinely studied alongside Abaloparatide and IGF-1 LR3 in longevity-focused compound panels. Researchers investigating myostatin pathway research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that effective in Duchenne muscular dystrophy models has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All ACE-031 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2 trial: significant muscle mass increase vs placebo
- Simultaneous bone density improvements
- Effective in Duchenne muscular dystrophy models
Ideal For
- Myostatin pathway research
- Muscle hypertrophy studies
- Bone mass research
- Sarcopenia investigation
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on ACE-031. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2 trial: significant muscle mass increase vs placebo
Simultaneous bone density improvements
Effective in Duchenne muscular dystrophy models
Third-Party Verified Every Batch
Each vial of ACE-031 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
